-
公开(公告)号:US20090124642A1
公开(公告)日:2009-05-14
申请号:US12229682
申请日:2008-08-25
申请人: Augusto Canavesi , Marco Villa , Ales Gavenda , Jiri Faustmann , Judith Aronhime , Ettore Gibatti , Alexandr Jegorov
发明人: Augusto Canavesi , Marco Villa , Ales Gavenda , Jiri Faustmann , Judith Aronhime , Ettore Gibatti , Alexandr Jegorov
IPC分类号: A61K31/517 , C07D239/94
CPC分类号: C07D239/94
摘要: The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof.
摘要翻译: 本发明提供了一种新型的埃罗替尼盐酸结晶形式,其制备方法及其制剂。
-
2.
公开(公告)号:US20100256392A1
公开(公告)日:2010-10-07
申请号:US12743568
申请日:2008-11-21
申请人: Ales Gavenda , Ettore Bigatti , Alexandr Jegorov , Augusto Canavesi , Pavel Vraspir , Judith Aronhime , Peter Lindsay MacDonald , Francesca Scarpitta , Marco Villa , Paolo Angioletti
发明人: Ales Gavenda , Ettore Bigatti , Alexandr Jegorov , Augusto Canavesi , Pavel Vraspir , Judith Aronhime , Peter Lindsay MacDonald , Francesca Scarpitta , Marco Villa , Paolo Angioletti
IPC分类号: C07D403/06
CPC分类号: C07D403/06
摘要: The present invention provides polymorphs of Sunitinib base and processes for preparation thereof.
摘要翻译: 本发明提供舒尼替尼碱基的多晶型物及其制备方法。
-
公开(公告)号:US20090118297A1
公开(公告)日:2009-05-07
申请号:US12257338
申请日:2008-10-23
申请人: Ondrej SIMO , Jiri Filipcik , Alexandr Martaus , Alexandr Jegorov , Ales Gavenda , Judith Aronhime , Pavel Vraspir , Tamas Koltai , Jiri Faustmann , Roman Gabriel
发明人: Ondrej SIMO , Jiri Filipcik , Alexandr Martaus , Alexandr Jegorov , Ales Gavenda , Judith Aronhime , Pavel Vraspir , Tamas Koltai , Jiri Faustmann , Roman Gabriel
IPC分类号: A61K31/506 , C07D417/14
CPC分类号: C07D417/12
摘要: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.
摘要翻译: 提供达沙替尼,其溶剂合物及其结晶形式,其制备方法及其药物组合物。
-
4.Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha 有权
标题翻译: 甲磺酸伊马替尼的多晶型形式以及制备新型结晶形式以及无定型和形成α的方法公开(公告)号:US20090264438A1
公开(公告)日:2009-10-22
申请号:US12148492
申请日:2008-04-17
IPC分类号: C07D401/14 , A61K31/496
CPC分类号: C07D401/04
摘要: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.
摘要翻译: 描述了甲磺酸伊马替尼的溶剂合物和结晶形式。 此外,描述了制备这种溶剂化物的方法和甲磺酸伊马替尼的结晶形式。
-
5.Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha 有权
标题翻译: 甲磺酸伊马替尼的多晶型形式以及制备新型结晶形式以及无定型和形成α的方法公开(公告)号:US20080090833A1
公开(公告)日:2008-04-17
申请号:US11796573
申请日:2007-04-27
IPC分类号: A61K31/497 , C07D239/20
CPC分类号: C07D401/04
摘要: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.
摘要翻译: 描述了甲磺酸伊马替尼的溶剂合物和结晶形式。 此外,描述了制备这种溶剂化物的方法和甲磺酸伊马替尼的结晶形式。
-
公开(公告)号:US20100256158A1
公开(公告)日:2010-10-07
申请号:US12814916
申请日:2010-06-14
申请人: Ondrej SIMO , Jirí Filipcik , Alexandr Martaus , Alexandr Jegorov , Ales Gavenda , Judith Aronhime , Pavel Vraspír , Tamás Koltai , Jirí Faustmann , Roman Gabriel
发明人: Ondrej SIMO , Jirí Filipcik , Alexandr Martaus , Alexandr Jegorov , Ales Gavenda , Judith Aronhime , Pavel Vraspír , Tamás Koltai , Jirí Faustmann , Roman Gabriel
IPC分类号: A61K31/496 , C07D417/14 , A61P35/00
CPC分类号: C07D417/12
摘要: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.
摘要翻译: 提供达沙替尼,其溶剂合物及其结晶形式,其制备方法及其药物组合物。
-
7.Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α 有权
标题翻译: 甲磺酸伊马替尼的多晶型形式和制备新型结晶形式以及无定型和形成α的方法公开(公告)号:US07977348B2
公开(公告)日:2011-07-12
申请号:US12148492
申请日:2008-04-17
申请人: Alexandr Jegorov , Miloslav Chudík , Judith Aronhime , Ale{hacek over (s)} Gavenda , Ji{hacek over (r)}í Faustmann
发明人: Alexandr Jegorov , Miloslav Chudík , Judith Aronhime , Ale{hacek over (s)} Gavenda , Ji{hacek over (r)}í Faustmann
IPC分类号: A61K31/505
CPC分类号: C07D401/04
摘要: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described. The structure diagram below shows the chemical structure of imatinib mesylate.
摘要翻译: 描述了甲磺酸伊马替尼的溶剂合物和结晶形式。 此外,描述了制备这种溶剂化物的方法和甲磺酸伊马替尼的结晶形式。 下面的结构图显示了甲磺酸伊马替尼的化学结构。
-
公开(公告)号:US20120165364A1
公开(公告)日:2012-06-28
申请号:US13412586
申请日:2012-03-05
申请人: Nicola Diulgheroff , Francesca Scarpitta , Alessandro Pontiroli , Adrienne Kovacsne-Mezei , Judith Aronhime , Alexandr Jegorov
发明人: Nicola Diulgheroff , Francesca Scarpitta , Alessandro Pontiroli , Adrienne Kovacsne-Mezei , Judith Aronhime , Alexandr Jegorov
IPC分类号: A61K31/439 , A61P11/06 , A61P11/00 , C07D491/08
CPC分类号: C07D451/12 , C07D451/10
摘要: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.
-
公开(公告)号:US08846926B2
公开(公告)日:2014-09-30
申请号:US13339042
申请日:2011-12-28
申请人: Nicola Diulgheroff , Francesca Scarpitta , Alessandro Pontiroli , Adrienne Kovacsne-Mezei , Judith Aronhime , Alexandr Jegorov
发明人: Nicola Diulgheroff , Francesca Scarpitta , Alessandro Pontiroli , Adrienne Kovacsne-Mezei , Judith Aronhime , Alexandr Jegorov
IPC分类号: C07D491/08 , C07D451/12 , C07D451/10
CPC分类号: C07D451/12 , C07D451/10
摘要: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.
摘要翻译: 本发明涉及噻托溴铵的新型结晶形式,其制备方法及其在药物制剂中的应用。
-
公开(公告)号:US08163913B2
公开(公告)日:2012-04-24
申请号:US11643001
申请日:2006-12-19
申请人: Nicola Diulgheroff , Francesca Scarpitta , Alessandro Pontiroli , Adrienne Kovacsne-Mezei , Judith Aronhime , Alexandr Jegorov
发明人: Nicola Diulgheroff , Francesca Scarpitta , Alessandro Pontiroli , Adrienne Kovacsne-Mezei , Judith Aronhime , Alexandr Jegorov
IPC分类号: C07D291/18
CPC分类号: C07D451/12 , C07D451/10
摘要: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.
摘要翻译: 本发明涉及噻托溴铵的新型结晶形式,其制备方法及其在药物制剂中的应用。
-
-
-
-
-
-
-
-
-